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Welcome
We are very pleased to welcome all of you in Utrecht to the fourth edition of the Utrecht - WHO Collaborating Centre 
for Pharmacoepidemiology and Pharmaceutical Policy Analysis Winter Meeting. The meeting brings together around 50 
researchers and policy makers from many different countries. 
The meeting will start on Thursday with young researchers from different professional backgrounds who will discuss their 
ongoing or planned work. We sincerely hope that these discussions will contribute to bringing evidence-based policy 
making on pharmaceuticals to a higher level. 
We have chosen “Bridging the worlds of medicines and medical devices” as central theme for the second day. This day will 
build on the outcomes of the Priority Medical Devices project produced under the direction of Josée Hansen. This project 
was initiated in 2007 by WHO in collaboration with the Dutch Ministry of Health, Welfare and Sports to determine whether 
medical devices currently on the market were meeting the needs of health care providers and end-users throughout the 
world and if not, to propose research to identify—and action to remedy—inadequacies or shortcomings. Invited speakers 
including those involved in the Priority Medical Devices project will discuss differences and similarities between medicines 
and medical devices and opportunities for joint learning.The meeting aims to involve all participants in summarising key 
lessons learned and identifying research subjects in the field of medical devices and medicines.
We would like to thank all of you for your contributions in advance and hope that you will continue to contribute by 
sharing your thoughts and expertise throughout the meeting. 
We wish you a fruitful meeting with exciting discussions and inspiring new thoughts!
On behalf of the Organizing Committee,
Bert Leufkens and Aukje Mantel 
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Location
Faculty Club 
Achter de Dom 7
3512 JN Utrecht
Phone: +31 (0)30 253 99 11
Date
Thursday, 5 January – Friday, 6 January, 2011
For all practical matters during the meeting, please contact: 
Aukje Mantel (a.k.mantel@uu.nl)
Mobile: +31 (0)6 227 360 17  
Organizing Committee 
Utrecht - WHO Collaborating Centre for Pharmacoepidemiology and Pharmaceutical Policy Analysis 
-  Aukje Mantel
- Josee Hansen
- Bart Wijnberg
- Bert Leufkens
Department of Essential Medicines and Pharmaceutical Policies, World Health Organization
-  Richard Laing
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Time schedule
Thursday 5 January 2012
 Presentations of ongoing pharmaceutical policy analyses
12:00-13:00 Registration, lunch
13:00-13:15 Welcome  Bert Leufkens (UU, MEB) + Richard Laing (WHO)
13:15-14:45 Paper discussion - 2 parallel sessions
 1a: Regulatory issues and challenges 
 (room: Belle van Zuylen)
 1b: Access to medicines (room: Kanunniken) 
14:45-15:30 Coffee break with poster session
15:30-17:00 Paper discussion - 2 parallel sessions
 2a: The added value of responsible use 
 of medicines (room: Belle van Zuylen)
 2b: Issues and challenges in rational use 
 of medicines (room: Kanunniken)
17:00-18:00 Drinks
18:30- Dinner (by invitation only)
Friday 6 January 2012
 ‘Everything you wanted to know about ................ but were afraid to ask’ – 
 Bridging the worlds of medicines and medical devices
From 8:30  Coffee
09:00-09:15 Welcome  Bert Leufkens (UU, MEB) + Richard Laing (WHO)
09:15-09:45 Commonalities and differences between 
 medicines and medical devices. 
 How to get the best of both worlds?  Josée Hansen (Dutch Health Care Inspectorate, former  
  project leader WHO Priority Medical Devices Project)
09:45-11:00 From research and development to market 
 launch/authorisation – research choices 
 from a public health perspective Medicines: Bert Leufkens (MEB)
   Medical devices: Gert Bos (BSI Group)
11:00-11:20 Tea / Coffee
11:20-12:30 Selection and health technology 
 management and assessment – clinical 
 choices in regions, countries and health 
 care facilities  Medicines: Richard Laing (WHO) 
   Medical devices: Geoffrey Graham (WHO)
12:30-13:15 Lunch   
13:15-13:30 Medicines and medical devices: 
 two worlds not so much apart anymore Erik Vollebregt (Axon Lawyers)
13:30-13:45 Bridging the academic worlds  Speaker Technical University (tbc) 
13:45-14:30 Break out session in small groups – 
 to discuss ways forward and research
 questions (clinical research, regulatory 
 science, HTA and policy analysis) 
14:30-14:50 Tea / Coffee
14:50-15:30 Group reporting and final discussions
15:30-15:40 Wrap up and future (research) outlooks  Josée Hansen + Bert Leufkens 
15:40-15:45 Day closure  Richard Laing + Bert Leufkens 
8Presentations of ongoing pharmaceutical policy analyses  
Session 1a – Thursday 5 January 2012
13.15 - 14.45 - parallel session - 
Regulatory issues and challenges
Session Chairs:  (tbc)
Nr Author Title
1 Ebbers A comparison of post-authorisation adverse events of biopharmaceuticals and small molecules
2 De Vries Reliability of a patient-reported adverse drug event questionnaire
3 Tafuri The level of transparency amongst regulatory agencies: the case of withdrawn and refused  
 applications
4 Putzeist Reasons for failure of new active substances in the EU: was it the drug or was it the   
 development plan?
Session 1b - Thursday 5 January 2012
13.15 - 14.45 - parallel session -  
  
Access to medicines  
Session Chairs:  (tbc)
Nr Author Title
5 Onwuka Pharmaceutical Quality and Access in Nigeria: Evaluation of the Mobile Authentication Technology  
 and stakeholder perceptions on quality and access 
6 Hessels The reasons behind a regulatory change around Tumour Necrosis Factor alpha inhibitors in  
 Portugal and the impact on utilisation
7 Jünger Legal and policy barriers to opioid availability in 12 European countries: results from a WHO self- 
 assessment checklist for national situation analysis
8 Vranken Legal and regulatory barriers in accessing opioid medicines in twelve European countries
Session 2a - Thursday 5 January 2012
15.30 - 17.00 - parallel session -
  
The added value of responsible use of medicines 
Session Chairs:  Veronika Wirtz (INSP) and Anke Hövels (UU)
Nr Author Title
9 Wahlster Access to high cost medicines: a systematic review of the literature
10 Stephens Variation in the use of NICE approved cancer drugs
11 Tariq Disease trajectory economic evaluations: moving towards better practice
12 Oliveira-Martins General practitioners’ views and attitudes on generic medicines in Portugal
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Session 2b - Thursday 5 January 2012
15.30 – 17.00  - parallel session - 
  
Issues and challenges in rational use of medicines
Session Chairs:  (tbc)
Nr Author Title
13 Hernandez Long-term evidence on the effects of the regulatory warnings and increased media coverage on  
 paroxetine use and other SSRIs
14 Bijlsma The influence of guideline changes on user prevalence of benzodiazepine: age, period and  
 cohort effects
15 Ebenezer Pen-injecte2d insulin therapy: experiences and views of diabetic patients in Nigeria
16 Ivanovska Measuring medicines use in children under 5: methodological issues and analysis of progress  
 1990-2009
Posters - Thursday 5 January 2012
14.45 - 15.30
Nr Author Title
17 Ankrah Influence of adherence on switching from first to second line treatment among HIV patients in  
 Ghana: a matched case-control study
18 Gefenaite Effectiveness of the influenza A (H1N1)pdm09 vaccine in a community-based sample
19 Hoebert Identification of priority policy research issues on access to medicines in low and middle income  
 countries
20 Philbert The 2009 H1N1 influenza A virus outbreak: adherence to national prescription guidelines for  
 oseltamivir
21 Sagwa The risk of ototoxicity in patients concomitantly treated for drug resistant-TB and HIV-1 infection
22 Tetteh Outcomes of a post-exposure prophylaxis program at the Korle-Bu Teaching Hospital (KBTH) in  
 Ghana
10
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List of participants UU-WHO winter meeting 5 + 6 January 2012 
(as of 22 December 2012)
 Amr Makady Utrecht University, the Netherlands
 Anke Hövels Utrecht University, the Netherlands
 Anne Gosselin Access to Medicines Foundationthe, the Netherlands
 Arjan van Drongelen RIVM, the Netherlands
 Artur Moura University of Lisbon, Portugal
 Aukje Mantel Utrecht University, the Netherlands
 Barbara Kashi Carasso Carashi Consult, the Netherlands
 Barikpoar Ebenezer Birmingham City University, United Kingdom
 Bart Wijnberg The Netherlands
 Benard Miregwa Ministry of Medical Services, Kenya
 Bert Leufkens Utrecht University, the Netherlands
 Chioma Joy Onwuka University of London, United Kingdom
 Christine Häfele-Abah German Medical Aid Organization action medeor e.V., Germany
 Daniel Ankrah Korle-Bu Teaching Hospital, Ghana
 Daphne Philbert Utrecht University, the Netherlands
 Erik Vollebregt Axon Lawyers, the Netherlands
 Evans Sagwa Management Sciences for Health, Namibia
 Francisco Hernandez Utrecht University, the Netherlands
 Geoffrey Graham WHO, Switzerland
 Gert Bos BSI Group, the Netherlands
 Giovanni Tafuri AIFA / Utrecht University, Italy
 Hans Ebbers Utrecht University, the Netherlands
 Joëlle Hoebert Utrecht University, the Netherlands
 Jolanda de Bie SIR Institute for Pharmacy, Practice and Policy, the Netherlands
 Josee Hansen Dutch Health Inspectorate, the Netherlands
 Katrina Perehudoff HAI Europe / Ghent University, the Netherlands / Belgium
 Kim Notenboom RIVM / CBG-MEB, the Netherlands
 Kirti Narsai PIASA, South-Africa
 Luqman Tariq GSK / Utrecht University, the Netherlands
 Maarten Bijlsma University of Groningen, the Netherlands
 Marjolein Vranken Utrecht University, the Netherlands
 Michelle Putzeist Utrecht University, the Netherlands
 Niamh Herlihy Access to Medicines Foundation, the Netherlands
 Nina Winters Utrecht University, the Netherlands
 Peter Stephens IMS Health, United Kingdom
 Philip Wahlster Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
 Priya Bahri European medicines Agency, United Kingdom
 Raymond Tetteh Korle-Bu Teaching Hospital, Ghana
 Richard Laing WHO, Switzerland
 Rose Higgins HAI Europe, the Netherlands
 Saskia Jünger University Hospital Bonn, Germany
 Sieta de Vries University Medical Center Groningen, the Netherlands
 Sofia Oliveira-Martins University of Lisbon, Portugal
 Sofie Hessels Utrecht University, the Netherlands
 Truus Janse-de Hoog CBG-MEB, the Netherlands
 Verica Ivanovska University of Stip, Macedonia
 Veronika Wirtz National Institute of Public Health, Mexico
 Waldo Weijers CBG-MEB, the Netherlands
 Wim Weber BMJ, United Kingdom
 Yaser Bazargani Utrecht University, the Netherlands
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Overview abstracts 5 January 2012
A Comparison of Post-Authorization Adverse events of Biopharmaceuticals and Small Molecules
Hans C. Ebbers1, Esraa Al-Temimi1, Ellen H.M. Moors2, Aukje K. Mantel-Teeuwisse1, 
Hubert G.M.  Leufkens1, Huub Schellekens2,3
1. Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology 
and Pharmacotherapy, Utrecht University, Utrecht, the  Netherlands
2. Copernicus Institute/Department of Innovation and Environmental Studies, 
Utrecht University, Utrecht, the Netherlands
3. Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), 
Faculty of Science, Utrecht, The Netherlands
Background
The nature of adverse events (AEs) associated with biopharmaceuticals differs from chemically synthesized, small 
molecules, which may require a tailored pharmacovigilance approach for these products. However, there are substantial 
differences between approved indications for small molecules and biopharmaceuticals. The question remains how much 
of the differences in observed post approval adverse events (AEs) can be attributed to differences in approved indications 
for these two groups.
Objectives
To investigate if the nature of AEs identified post-authorization for biopharmaceuticals differ from the AEs of small 
molecules within the same therapeutic class.
Methods
All safety related changes to the Summary of Product Characteristics during 2004-2011 were analyzed. All products (small 
molecule and biopharmaceuticals) classified in the Anatomic Therapeutic Classification System as “antineoplastic and 
immunomodulating agents” (‘L’) were included. Individual AEs were identified and classified according to MedDRA. Group 
differences were tested using 2-sided Fisher’s exact tests.  
Results
A total of 843 AEs were identified for 69 products. Of these, 440 belonged to biopharmaceuticals vs. 403 to small molecules. 
For biopharmaceuticals, 191(43.4%) of the AEs were reported for immunostimulants, 184 (41.8%) forimmunosuppressants 
and 65 (14.8%) for antineoplastic agents. The majority of the AEs of small molecules were reported for antineoplastic 
agents, which included 296 (73.4%) of AEs, 98 (24.3%) of the AEs were reported for immunosuppressants and 9 (2.2%) for 
endocrine therapies. AEs reported for products within the therapeutic subgroup of immunosuppressants  were compared. 
AEs of biopharmaceuticals were more often classified as ‘neoplasms’, 19% vs. 3% (p<0.01) and ‘Infections and infestations’ 
20% vs. 9% (p=0.02). AEs for small molecules were more often’ Renal & urinary disorders’ (p= 0.02) and ‘Blood & 
lymphatic system disorders’ 9% vs. 3% (P=0.04). 
Conclusion
The distribution of AEs identified post authorization differs for biopharmaceuticals and small molecules, even in products 
from the same therapeutic subgroup.
1
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Reliability of a patient-reported adverse drug event questionnaire
ST de Vries1, FM Haaijer-Ruskamp1, D de Zeeuw1, P Denig1
1. Dept. Clinical Pharmacology, University Medical Center Groningen, The Netherlands
Background
Regulatory authorities advise the use of patient-reported outcome (PRO) instruments in the measurement of concepts 
which are best known by patients, like symptomatic adverse drug events (ADEs). Recently, we developed a generic PRO 
questionnaire to assess ADEs and their nature regarding frequency, duration, timeline, burden, severity and causality. This 
checklist-based questionnaire contains a wide range of ADEs described in lay terms and categorized by body system.
Objective 
The objective of this study is to test the reliability and feasibility of the developed questionnaire. Specifically, the test-
retest reliability, the impact of the ADE- categorization, and the reliability of various recall periods will be assessed. 
Methods 
The study consists of two parts both having a serial cross sectional design.
Part 1. Test-retest reliability and reliability of ADE-classification:
150 Patients with type 2 diabetes will be randomly divided in three groups. They will have to complete the questionnaire 
twice, partly using different versions of the questionnaire. One group will receive the questionnaire with ADEs categorized 
in body systems at T0 while receiving the questionnaire without the categorization at T1. The reverse is the case for the 
second group. The third group receives the same questionnaire twice to assess the test-retest reliability. 
Part 2. Reliability of various recall periods:
200 Patients with type 2 diabetes are asked to keep a diary for recording possible ADEs during a period of 3 months, 
followed by the completion of the questionnaire. Patients are divided in groups and each group will receive a different 
recall period of the questionnaire.
The main outcome is the agreement in reported ADEs at body system level. The intraclass correlation coefficient will be 
used for assessing reliability. Differences between recall periods will be assessed using t-tests. Time needed to complete 
the questionnaire, and the percentage of missing items will be measured regarding the feasibility.
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The level of transparency amongst regulatory agencies: 
the case of withdrawn and refused applications
Giovanni Tafuri1,2, Francesco Trotta1, Hubert G.M. Leufkens2,3
 
1. Italian Medicines Agency (AIFA), Rome, Italy
2. Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
3. Medicines Evaluation Board (MEB), The Hague, The Netherlands
Background
A call for a greater transparency at the EMA and the FDA has been launched in the scientific community. Special 
attention has been posed in the US on the lack of disclosure of information related to drug applications withdrawn 
prior to the conclusion of the evaluation procedure or receiving negative opinion by the FDA. On the contrary, at the 
EU level this information is made publicly available by the EMA through the European Public Assessment Reports 
published on the Agency’s website.
Objective
This analysis has two main objectives: i) to evaluate the availability of published information on drug applications 
withdrawn prior to the conclusion of the evaluation procedure, or receiving negative opinion at the end of it, among 
different regulatory authorities; ii) to identify the reasons leading to withdrawals and refusals of medicinal products at the 
EMA during the regulatory review process.
Methods
A written query has been sent to relevant regulatory authorities  for which a contact detail was available. 
Reports on withdrawals of applications related to all therapeutic categories as well as negative opinions were retrieved 
from the EMA website. Cut-off date for data retrieval was 31 December 2010. Post-approval withdrawals, which are usually 
related to pharmacovigilance issues, were excluded. 
Results
The information on withdrawals is made publicly available just in the EU by the EMA and in Australia by the 
Therapeutic Goods Administration. With regard to the analysis on withdrawn/refused applications at the EMA, the 
majority of the active compounds were represented by four main categories: i) oncology/immunology drugs (34%), 
ii) CNS drugs (17%), iii) drugs for cardiovascular/metabolic diseases (16%), and iv) infectious diseases (14%). 
The reasons leading to a withdrawal of a drug application or refusal can be related both to quality, safety and 
efficacy issues, sometimes a combination of the three: 106 objections were due to efficacy deficiencies, while 27 to 
safety and 23 to quality. 
Within the efficacy objections, five main categories were identified, as follows: a) lack of clinical significance (44 out 
of 106), b) methodological issues (23 out of 106), c) PK issues including bioequivalence/non-inferiority (20 out of 
106), d) lack of statistical significance (13 cases), e) five cases related to GCP issues. 
Conclusions
Although there are still avenues for improvement of transparency in the regulatory authorities, the publication of the 
assessment reports of withdrawn and refused medicinal products seems a good starting point from a public health 
perspective. 
1 Drug regulatory authorities of Argentina, Australia, Brazil, Canada, Chile, China, Cuba, European Union, India, Japan, Mexico, Morocco, 
Namibia, New Zealand, Russia, Saudi Arabia, South Africa, Switzerland and the United States of America.
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Failed drugs study: Reasons for failure of new active substances in the EU: 
Was it the drug or was it the development plan?
M. Putzeist1,2, A.K. Mantel-Teeuwisse1, C.C. Gispen-De Wied2, A.W. Hoes2,3, H.G. Eichler4, 
H.G. Leufkens1,2
1 Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology & 
Clinical Pharmacology, Utrecht University, the Netherlands
2 Medicines Evaluation Board, The Hague, the Netherlands
3 Julius Center for Health Sciences & Primary Care, University Medical Center Utrecht, the Netherlands
4 European Medicines Agency, London, United Kingdom
Rationale
The high failure rate of new active substances in the European marketing authorisation procedure is a serious 
concern that threatens current and future innovative drug development and access to innovative medicines. [1]. In 
this study we assess the association of  the drug development plan and the benefit-risk assessment with marketing 
failure.
Methods
All marketing applications for new medicinal products with a first outcome in the centralized European marketing 
authorisation procedure between January 2009 and December 2010 were included. The development plan was divided 
in a learning phase and a confirmatory phase, each defined by five subvariables. An appropriate development plan 
was defined as having no major objection on any of these subvariables at day 120 of the marketing authorisation 
procedure. Determinants that described the benefit-risk assessment were clinical outcome (consisting of statistical 
significant effect on primary endpoint and serious safety issues) and clinical relevance. The study outcome was the 
opinion of the Committee for Medicinal Products of Human Use (CHMP) about marketing authorisation. Univariate 
relative risks and 95% confidence intervals (CI) were calculated for each determinant. A multivariate logistic regression 
analysis was conducted to assess to which extent the drug development plan or the benefit-risk assessment (clinical 
outcome or clinical relevance) were associated with marketing failure. 
Results
In total 68 applications for new active substances entered the marketing authorization procedure, of which 23 (34%) 
failed and 45 (66%) were approved to the market. Of these 68 drugs, 50 (73%) had deficits in the development plan: 
in the learning phase only (N=9 (13%)), confirmatory phase only (N=19 (28%)) or both (N=22 (32%)). Aggregated 
analyses demonstrate that having both an inappropriate learning and confirmatory phase is significantly associated 
with marketing failure (RR 5.3 (1.2-23.6). The multivariate analysis shows that deficits in the clinical development 
plan (OR 10.4 CI95% 1.7-63.3), clinical outcome (lack of a statistical significant effect on primary endpoint or serious 
safety issues) (OR 9.7 CI95% 2.1-46.2) and lack of clinical relevance (OR 7.5 CI95% 2.0-58.5) are all associated with 
marketing failure.
Conclusions 
An appropriate development plan, positive results on clinical outcomes and a validation of clinical relevance by regulators 
are very likely to lead to marketing authorisation, whereas deficits on any of these elements lead to intense discussions 
about marketing authorisation in which deficits of the development plan and clinical outcome, but in particular clinical 
relevance, are associated with marketing failure.
1. Eichler HG et al. New drug approval success rate in Europe in 2009; Nature Reviews Drug Discovery 2010: 9(355-356)
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Pharmaceutical Quality and Access in Nigeria: Evaluation of the Mobile 
Authentication Technology and stakeholder perceptions on quality and access
Chioma Joy Onwuka1, Barikpoar Ebenezer2,3, Obinna Ekwunife4
1 The School of Pharmacy, University of London 
2 Faculty of Pharmaceutical Sciences, University of Port Harcourt, Nigeria 
3 Birmingham City University, United Kingdom 
4 Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka
Rationale
There are very few studies involving qualitative field work to find out how different stakeholders perceive the 
problem of poor quality medicines and how it can be effectively tackled.  Also there is very limited research 
determining the impact in practice of initiatives against medicines counterfeiting.  This information is vital as it will 
guide development of interventions against medicines counterfeiting.  
Objectives
The aims of this research are to evaluate the Mobile Authentication Technology and to identify wider issues related 
to accessibility of good quality medicines, from the perspective of Nigerian stakeholders
Design 
Cross-country volume-weighted price analysis of a basket with 20 products in 15 countries in 2007 and 2008. 
Multivariable analysis was performed to account for differences on the gross domestic product, total pharmaceutical 
expenditure and the national employment in the pharmaceutical industry.
Methods
The study will be conducted in two phases.  The first phase will involve quantitatively analysing metformin tablets 
(tagged Glucophage® and the cheapest available generic versions) randomly sampled from retail outlets in Lagos, 
Nigeria via Packaging analysis and visual inspection, Near Infra Red spectroscopy and High Performance Liquid 
Chromatography.  Text messages will be sent as directed to authenticate the tagged Glucophage® tablets.  The 
responses will be compared with results of the chemical analysis.  The quality of the tagged Glucophage® samples 
will also be compared with the generic versions without the authentication tags.
The second phase will involve the use of semi-structured interview schedules for different groups of stakeholders; 
consumers, medicine sellers (community pharmacists, Patent Medicine Vendors, traders) and Policy makers.  Purposive 
sampling would be used to sample the consumers and medicine sellers while snowball sampling will be employed to 
recruit the policy makers.  Variables to be explored will be adapted from the socio-technical framework.
All quantitative data arising from the study will be analysed using the SPSS while Framework analysis will be used 
to analyse qualitative data.  
Conclusion
This study will help to validate the Mobile Authentication Technology and explore issues related to accessibility of good 
quality medicines and the use of the Mobile Authentication technology from an independent stand point.  This will aid 
formulation of recommendations for its implementation and future expansion.
5
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The reasons behind a regulatory change around Tumour Necrosis 
Factor alpha inhibitors in Portugal and the impact on utilisation.
Sofie Hessels1, Joëlle Hoebert1, Aukje Mantel-Teeuwisse1, José António Pereira da Silva2, 
Francisco Batel Marques3
1. UIPS, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht, The Netherlands 
2. Department of Rheumatology, University of Coimbra, Portugal
3. Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal 
Purpose
To assess the reasons behind a policy measure around Tumor Necrosis Factor alpha (TNFalpha) inhibitors in Portugal 
and to study whether the policy measure led to a change in the amount of TNFalpha inhibitor used in the treatment 
of rheumatoid arthritis in the Coimbra region. Furthermore, to compare the effect of this policy measure with the 
effects of a policy measure around TNFalpha inhibitors in Norway.
Method
A literature research was conducted and interviews were held (n=3) with people involved in the prescription and/or 
regulatory aspects around TNFalpha inhibitors. In addition monthly volume data (in packs and DDDs) from three TNFalpha 
inhibitors (adalimumab, etanercept and infliximab) were derived from the University Hospital of Coimbra (HUC Hospital) 
(Portugal) and from the Norwegian Institute of Public Health. For both countries the data covered the period January 2003 
- December 2010. Data on gender and age were available from the University Hospital of Coimbra. 
Results
The policy measure in Portugal was taken to facilitate prescription of TNFalpha inhibitors by extending the prescription to 
the outpatient setting. However, in the HUC hospital a decrease in volume of TNFalpha inhibitors between January 2003 
and December 2010 was found: formula of the trendline in defined daily doses (DDDs) before the policy measure: y = 
63,218x + 1993,8 (R2 = 0,6199) and after the policy measure: y = 12,573x + 5808,6 (R2 = 0,0295). In Norway a decrease 
in volume of TNFalpha inhibitors was also found but this was the intended purpose of the policy measure (y = 0,0283x + 
0,4485 (R2 = 0,9118) versus y = 0,0156x + 1,6967 (R2 = 0,8366)). The average age of patients using TNFalpha inhibitors 
increased a little in time after 2005 till 2010 from 45 till 51.  The average age found for female patients was higher than 
male patients, except for adalimumab in 2004-2006. The Portuguese patient association (ANDAR) was pleased with the 
policy measure because it should lead to an easier access to treatment with TNFalpha inhibitors. This was in contrast with 
rheumatologists, which were not pleased by the fact that internist may also prescribe TNFalpha inhibitors and by the lack 
of control in private prescribing. 
Conclusion
Policy measures do not always seem to work out as expected as shown by this example. Therefore when designing 
a policy measure, it is important to involve all concerned parties to discuss how and if the policy measure can reach 
its main goal. 
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Legal and policy barriers to opioid availability in 12 European countries: 
results from a WHO self-assessment checklist for national situation analysis
Saskia Jünger1, Marjolein Vranken2, Tom Lynch3, Sheila Payne3, Kees de Joncheere4, 
Willem Scholten5, Lukas Radbruch1,6
1. Department of Palliative Medicine, University of Bonn
2. Utrecht Institute for Pharmaceutical Sciences, Division Pharmacoepidemiology & Clinical Pharmacology, 
Utrecht University 
3. International Observatory on End of Life Care, Division of Health Research, Lancaster University
4. WHO Country Office Ukraine, Kiev, Ukraine
5. Access to Controlled Medicines, World Health Organization
6. Centre for Palliative Medicine, Malteser Hospital Bonn/Rhein-Sieg
Aims
A sound analysis of legal and policy barriers to opioid availability is a prerequisite for improving access to opioids 
on a national level. The WHO Guidelines “Ensuring balance in national policies on controlled substances” include a 
country assessment checklist for analysing potential barriers to opioid availability. Within the ATOME project it was 
aimed at having country teams from the 12 target countries complete the checklist as a basis for their national action 
plans on improving access to opioids.
Methods
The teams were invited to complete the checklist and hereby explore to what extent the WHO Guidelines are met in 
their country. Each item of the checklist can be answered with yes/no/unknown, to be specified with explanations 
and a note as to whether action is required for that specific topic.  
Results
To date, checklists from 8 countries are available for analysis. The results show that practical barriers do not always 
coincide with the formal / legal positive provisions for access to opioids. For example, 1 country stated that despite 
having a provision in their law that controlled medicines are absolutely necessary for medical and pharmaceutical care, 
health care professionals could not be free from fear of investigation, prosecution or disproportionate punishment 
when prescribing or administering opioids. Likewise, 2 countries reported an absence of training courses on rational 
use of controlled medicines for physicians, pharmacists and nurses whilst having a government policy that urges 
medical, pharmaceutical and nursing schools to provide education on this issue.
Conclusion
The results confirm findings from previous research that there may be discrepancies between the legal provisions 
regarding rational use of opioids and the actual barriers in medical practice. The findings highlight the need for a 
combined approach on the levels of legislation, policy, health care and education for an effective improvement of 
access to opioids for medical use.
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Legal and regulatory barriers in accessing opioid medicines 
in twelve European countries
 
Marjolein Vranken1, Saskia Jünger2, Tom Lynch3, Aukje Mantel-Teeuwisse1, Marie-Hélène Schutjens1
1.Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, 
Utrecht University, Utrecht, the Netherlands
2. Department of Palliative Medicine, University of Bonn, Bonn, Germany
3. International Observatory on End of Life Care, Division of Health Research, Lancaster University, Lancaster, 
United Kingdom
Aims
Aims
Methods
A method to identify legal and regulatory barriers to opioid medication was developed focusing on six different categories 
of barriers (importation/exportation, prescribing, dispensing, manufacture, registration and miscellaneous) in twelve 
European countries (Bulgaria, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, Poland, Serbia, Slovakia, Slovenia 
and Turkey). Legislation was obtained from key experts who were selected based on their expertise in the field of 
pharmaceutical law and health policy. The legislation was analyzed (‘quick scanned’) using WHO criteria. Overly restrictive 
provisions were identified, as well as provisions that contain stigmatizing language and incorrect use of definitions. 
The selected provisions were independently scored by two reviewers into two categories: 1) a probable barrier and 2) a 
potential barrier. A barrier was recorded if both reviewers concurred witch each other. 
Results
Legislation was obtained from eleven European countries. All eleven countries showed legal and regulatory barriers 
in the areas of prescribing (most frequently observed barrier). Several (but not all) countries showed barriers in other 
categories, but no barriers concerning the manufacture of opioid medicines were identified. Ten countries showed 
stigmatizing language and incorrect use of definitions in their legislation. In total five countries showed more than 
twenty-four barriers in their legislation. The number of identified barriers was the lowest for Cyprus (<15).  
Conclusion and discussion
This study shows that legal and regulatory barriers can be identified using a quick scan method. Commonalities in 
the selected countries include the areas of prescribing and the use of stigmatizing language and incorrect use of 
definitions. Additional research is needed to assess the extent of the barriers and their impact on access to opioid 
medicines. 
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Access to high cost medicines: a systematic review of the literature
Philip Wahlster1
1. Interdisciplinary Centre for Public Health and Health Technology Assessment (IZPH) 
at the University of Erlangen-Nuremberg (FAU)
Problem Statement
Healthcare systems in western countries face increased rationing of drugs due to the incresaing costs related to medicines. 
There is an ongoing debate regarding the availability and funding of newer expensive medicines, often termed as “high 
cost medicines”.
Objective
Aim of this project is to provide a critical review of the literature pertaining to high cost drugs. The specific objectives 
were to identify the viewpoints and perceptions of different stakeholders regarding “access to high cost drugs” and 
to identifying barriers which influence the access and usage of high cost drugs. This knowledge would help us to 
formulate policy questions which inturn could be neficial to improve access for patients. 
Stakeholders involved
Politicians, decision-makers, physicians, patients, public.
Methodology
Retrospective review of the literature published between 1999 to 2010: Different databases were searched for papers 
about high costs drugs. We found 374 papers and selected 39 for the final analysis and synthesis of the systematic 
review.  
Results
Many stakeholders are concerned about the challenges regarding high cost drugs. They worry that physicians might not 
consider certain medicines if they cause high out-of-pocket drug costs for patients. Patients want to be informed about all 
treatment options, however, even if they cannot afford them. Viewpoints of the stakeholders and barriers to access were 
identified on several levels.
Conclusion
This review concludes that stakeholders agree that access could be promoted through transparency and involvement 
of all stakeholders, especially patients and public in the decision making process. The relationship of physicians 
and patients are affected by high cost drugs. Moral issues and the rule of rescue could have a big influence on the 
decisions regarding increasing inequalities, especially empowered by the media. Barriers normally lead to inequality. 
There is a complex interdependence of access limitations, opportunity costs and the fourth hurdle. 
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Variation in the use of NICE approved cancer drugs 
Stephens P1,2, Wu J1, Anger C1, Casey V1
1. IMS HEALTH 
2. WHO Collaborating Centre for Pharmacoepidemiology and 
Pharmaceutical Policy Analysis, Utrecht University, Utrecht, the Netherlands
Introduction
An alternative to comparison of total volumes  across countries may be to apportion volume by indication using 
sample data. This paper examines use in advanced Non Small Cell Carcinoma (aNSCLC), metastatic Colorectal Cancer 
(mCRC) and advanced Renal Cell Carcinoma (aRCC).
Objectives
To describe:
i. use according to NICE guidelines across countries 
ii. the influence of treatment size, age and relative adherence to NICE guidelines
iii. the clinical impact of variation
  
Settings 
(A) Physicians in France, Germany, Italy, Spain and UK contributing pseudonymised records to IMS’ sample database, 
Oncology Analyzer between April 2010-March 2011 (aNSCLC=2651 records; 1st line mCRC=2156; 1st line aRCC=724; 7 
drugs assessed and approved for the 3 conditions, 7969 records).
(B) Pharmacies releasing data to IMS on total volume dispensed
Outcome measures – use within NICE guideline by country
(1)  Total kilograms divided by number of people dying from lung, colorectal and 
 kidney cancer as appropriate (Globocan, 2008)
(2)  % eligible patients treated 
(3)  Planned treatment size
(4)  Proportion treated aged >70 
(4)  Impact of variation on costs, survival, Quality Adjusted Life Years
Results – use within NICE guideline
(1)  Total kilograms used for mCRC and aRCC similar across countries. 
 Total kilograms for aNSCLC in UK significantly lower. 
(2)  % eligible population treated within NICE guidelines significantly higher in the UK 
(3)  Significant differences in planned treatment size in aNSCLC but insufficient to explain volume variation
(4)  No consistent evidence of bias against elderly 
(4)  Limited or no efficacy data or models for majority of non-recommended regimens. Where assumptions  
 deemed to be reasonable, results suggest NICE guidance impact on survival greater for mCRC but QALY  
 impact greater for aRCC.  
Discussion 
aNSCLC results suggest differences in diagnosis, referral or attitudes to treatment/toxicity. Impact analysis thwarted 
by the absence of data. 
Contributions
PS devised the concept and method, the summary of the NICE guidelines and cost-effectiveness data and for all data 
analysis. VC, JW and CA extracted data and advised on interpretation of data elements.
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  Disease Trajectory Economic Evaluations: Moving Towards Better Practice
Luqman Tariq1,2, Anke Hövels1, Jan Raaijmakers1,2
1. Utrecht Institute for Pharmaceutical Sciences, Division Pharmacoepidemiology & 
Clinical Pharmacology, Utrecht, The Netherlands
2. GlaxoSmithKline, Zeist, The Netherlands
Abstract 
In the Netherlands, economic evaluations are used by health policy decision makers to take policy and reimbursement 
decisions about the introduction of new health technology. Currently, health policy decisions are taken based on 
cost-effectiveness ratios resulting from economic evaluations of single interventions. Also, economic evaluations of 
different alternatives from different health care domains (prevention, cure, care) are compared to each other while 
taking health policy decisions on health care spending. In addition, methodology applied in economic evaluations 
vary greatly in terms of model inputs, model assumptions, costs and effects identification, measurement and 
valuation. 
In this paper, we provide the rationale for performing disease trajectory economic evaluations which can help base 
health policy decision making on cost-effective ratios from a whole disease trajectory. A disease trajectory economic 
evaluation would provide an overview of the cost-effectiveness of the whole disease trajectory, from preventive 
measures till the required care at home, resulting in a disease trajectory cost-effectiveness ratio (DTCER). This ratio 
would not be a sum of individual ICERs of interventions, but would be calculated based on a disease-trajectory chain 
model, one unique core set of assumptions, and a consistent way of identification, measurement and valuation of 
costs and effects of interventions which are part of the disease trajectory. Performing disease trajectory economic 
evaluations requires (i) Markov chain-models in order to provide an overview of the cost-effectiveness of the disease 
trajectory,  (ii) consistency in the methodology applied in economic evaluations in order to make the study results 
comparable, and (iii) a different societal threshold value for costs per Quality Adjusted Life Year (QALY) gained. 
Disease trajectory economic evaluations can be of added value to health policy decision makers to maximize health 
gains while spending the health care budget, meanwhile leading to comparable study results based on consistent 
methodology applied in economic evaluations.
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General practitioners’ views and attitudes on generic medicines in Portugal
Sofia Oliveira Martins1, Artur Moura1, Jose Cabrita1
1. Faculty of Pharmacy - University of Lisbon, iMed.UL - Research Institute 
for Medicines and Pharmaceutical Sciences, Lisbon, Portugal
Background
Over the past decades, drug expenditure has risen rapidly in most of the countries and a trend to control these 
increases is to encourage the use of generic drugs (GD). 
Portuguese market share of GD is low as compared with European countries. The proportion of GD available on 
prescription has increased substantially in recent years, but market share of GD by volume only amounted to 17.5% 
in May 2010. 
Physicians are at the centerpiece of medication use process and it is recognized that prescription is the main 
decision-making process regarding the consumption of a drug. Thus it is important to examine the prescriber’s 
perceptions about GD.
Objective
To characterize beliefs and attitudes of prescribers in relation to GD.
Methodology
Cross sectional study (April-September 2009). Information was gathered from a panel of 140 general practitioners’ 
working in health centers from the 5 Health Regions by interview (structured questionnaire). Data regarding prescribed 
therapy to patients was based on medical records (15 patients per doctor). 
Results
Response rate was 86.4%. 
Most respondents (over 3/4) considered that GD have effectiveness and safety at least equivalent to those of 
branded drugs, but admitted that economic power of their patients was a decisive factor in the option of prescribing 
a GD (>85%). 
Nearly half of physicians (45%) considered there is no guarantee of bioequivalence of the GD relatively to the 
original product and that replacement of an original drug by the corresponding GD would compromise the patient’s 
adherence to therapeutic regimens (35%).
Almost 3/4 of the respondents considered that their patients had a similar degree of confidence in GD relatively to 
branded drugs.
The surveyed physicians prescribed a total of 5342 medicines (1765 patients), from which 48.7% were generics. The 
higher percentage of generic prescriptions occurred for Digestive (64.3%), Endocrine/metabolic/nutritional (55.3%) 
and Psychological (51.2%) conditions.
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Long-term evidence on the effects of the regulatory warnings 
and increased media coverage on paroxetine use and other SSRIs 
J.F. Hernandez1, A.K. Mantel-Teeuwisse1, G.J.M.W. van Thiel2, J.A.M. Raaijmakers1,3, T. Pieters1,4
1. Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for 
Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
2. Julius Centre for Health Sciences and Primary Care, 
University Medical Centre Utrecht, Utrecht, The Netherlands
3. GlaxoSmithKline, External Scientific Collaborations Europe, Zeist, The Netherlands 
4. EMGO, VU Medical Centre, Amsterdam, The Netherlands
Background
The SSRIs and suicidality controversy has played an important role in triggering public debates on the integrity of 
the pharmaceutical system. We used this controversy to assess if there is an association between the regulatory 
warnings and increased scientific and Dutch and British newspapers coverage on SSRI use in the Netherlands (NL) 
and in the United Kingdom (UK) from January 2000 to December 2009.
Methods
Monthly SSRIs sales data for the NL and the UK (IMS Health) was calculated into DDD/1000 inhabitants/day. The GIP-
database provided yearly SSRI insurance/claims data stratified by age group (only NL). Use trends were analyzed with time 
series analyses to estimate associations between SSRIs use and the intervention (warnings and newspaper coverage). 
Results
From 2000 to 2009, SSRI use increased 2-fold in the UK and 1.7-fold in NL. UK used 1.5-fold (SD:0.14) more SSRIs 
than NL. Paroxetine irrecoverable dropped in UK after May 2002 (pre-warnings), whereas citalopram use escalated 
from 2000 to 2009. This growth on citalopram use was also perceivable in the NL. The use of paroxetine moderately 
decreased in the NL after January 2006. Paroxetine was the most used SSRI in the NL, whereas in the UK was 
fluoxetine. SSRIs use within Dutch age groups showed 13-fold drop of paroxetine after 2000 in pediatrics, 5.7-fold 
after 2002 in adolescents, 4-fold after 2001 in young adolescents, 1.2-fold increment until 2004, followed by 1.4-fold 
drop in adults, and 1.2-fold growth in elderly until 2009. 
Conclusion
Neither the warnings, nor increased media attention were associated with less SSRI’s use in both countries. On 
the contrary, SSRI’s use doubled during the study period. However, stratified analyses per individual SSRI and age 
groups showed a significant drop of paroxetine (most directly associated SSRI with suicidality). Thus, warnings and 
negative media attention about this controversy did not affect overall SSRI prescription behavior by Dutch and British 
doctors.
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The influence of guideline changes on user prevalence of benzodiazepine: 
age, period and cohort effects 
Bijlsma MJ (PE2, RUG), Bos HJ (PE2, RUG), De Jong van den Berg LTW (PE2, RUG), Hak E (PE2, 
RUG), Janssen F (PRC, RUG)
Rationale
Benzodiazepine has a large number of users in Western countries, a large proportion of which is a chronic user. 
Chronic use is, among others, caused by dependency. In order to curb benzodiazepine use, general practitioners 
were advised to prescribe sparsely to new users in 2002.
Objectives
To examine the effect of guideline changes on the user prevalence of benzodiazepine by looking at birth cohort 
trends in addition to age and period trends.
Methods
We used drug dispensing data from community pharmacies covering 500,000 individuals (IADB.nl). Our study population 
consists of individuals aged 18 to 85 in the Netherlands in the period 1994-2008. First, we compared age specific 
prevalences plotted by period (age-period plots) with age specific prevalences plotted by birth cohort (age-cohort plots). 
Secondly, we specified an age-period-cohort model. 
Results
User prevalence, the number of individuals with a minimum of one benzodiazepine prescription per 1000 population, 
decreases with time. Older birth cohorts have higher user prevalence than younger birth cohorts. User prevalence of 
benzodiazepine remains stable within birth cohorts, possibly because of addictive effects. As older birth cohorts leave the 
population, overall benzodiazepine user prevalence declines. The guideline change appears to have affected the youngest 
birth cohorts especially.
Conclusions
The combined examination of age, period and birth cohort patterns provides additional insight for benzodiazepine and 
can aid the description, explanation and prediction of trends in drug use.
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Pen-injected Insulin Therapy: Experiences and Views of 
Diabetic Patients in Nigeria
Barikpoar Ebenezer1,2, Chioma Joy Onwuka3, Obinna Ekwunife4
1. Faculty of Pharmaceutical Sciences, University of Port Harcourt 
2. Birmingham City University, United Kingdom 
3. The School of Pharmacy, University of London 
4. Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka
Rationale
There are very limited studies conducted in Nigeria to describe patients’ experiences of their transition from syringe-
injected insulin therapy to pen-injected insulin therapy and the impact on their diabetic management and social 
lives.
Objectives
The objectives  of this research are to document the experiences of patients in their transition to the use of pen-
injected insulin therapy in the context of their glycemic control, safety and economic implications, describe the 
advantages and disadvantages of syringe-injected and pen-injected insulin therapy from patients’ perspectives, 
assess the satisfaction of patients on pen-injected insulin therapy compared to syringe-injected insulin therapy and 
make recommendation on the use of insulin administration devices from the perspectives of patients.
Method
A descriptive cross sectional study will be conducted.  Diabetic patients meeting the inclusion criteria will be recruited 
from community pharmacies in Port Harcourt Nigeria.  Data will be obtained using Semi structured interviews with 
the selected participants and from patients’ medical record of their HbA1C and blood glucose levels.  Interviews will 
be transcribed verbatim and analysed using the constant comparative analysis approach while all quantitative data 
will be analysed using the SPSS statistical software.
Outcome
The study will inform future health policy and provision to diabetic patients based on the information obtained from 
patients’ perspectives on the experiences of using different insulin administration devices.
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Measuring Medicine Use in Children Under 5: 
Methodological issues and analysis of progress 1990-2009
Verica Ivanovska1 , Kathleen Holloway2, Dennis Ross-Degnan3
1. Faculty of Medical Sciences, Stip, Macedonia (previously World Health Organization, Geneva); 
2. World Health Organization, Regional Office S.E.Asia, India; 
3. Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, USA 
 
Background
Many low- and middle-income countries (LMIC) have tried to improve treatment of child acute illnesses, but scant 
evidence exists about progress. 
Objectives
To undertake a systematic review of studies in order to provide an overview of medicine use in children under 5 
years in LMIC and identify effective interventions.
Search strategy and mathods
Quantitative data was systematically extracted from published and unpublished studies from 1990 to 2009 on medicine 
use in children under 5 years in primary health care in LMIC.  Pertinent data was entered in WHO database providing 
details on study setting, methodology, interventions, and outcomes based on standard indicators of medicines use. 
To estimate trends over time, the average of each indicator was calculated (limited to baseline data for interventions) by 
study year, region, facility ownership and prescriber type.  To estimate intervention impacts, summary effect sizes was 
calculated for studies meeting accepted design criteria.  The indicator with the greatest effect size (GES) and the median 
effect size (MES) over all indicators were examined.
Results
Data was extracted for 394 studies conducted in 78 countries; 75% reported  data  from  the  public sector and 25% 
from  the  private-for-profit  sector.  From 1992 to 2009, we observed no improvements in percentage of pneumonia 
cases treated appropriately with antibiotics and non-pneumonia cases receiving  inappropriate antibiotics.  Treatment of 
childhood diarrhoea remains poor in regards to diarrhea cases treated with ORS and diarrhea cases treated inappropriately 
with antibiotics, and only use of antidiarrheals shows improvement.  Public sector practices tended to be better than 
private sector.  
Interventions were reported in 57% of studies, but of those only 20% used adequate study design.  Multi-component 
interventions tended to have larger effects than single-component ones. 
Conclusions 
Treatment of child illness remains suboptimal in LMIC. Although many well-designed interventions reported positive 
effects, there has been no  observable improvement in practice. 
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Influence of adherence on switching from first to second line treatment 
among HIV patients in Ghana: A matched case control study
D. Ankrah1,2, A.K. Mantel-Teeuwisse1, M. Lartey2,3, M.L. De Bruin1, 
I. Agyepong4, R. Laing5, H.G.M. Leufkens1
Background
As we embark on a lifelong activity of antiretroviral therapy (ART), adherence to selected treatment regimen stands 
out as one of the most important areas to tackle if we should make any gains. Non-adherence to treatment will 
certainly jeopardize treatment benefits as a result of treatment failure. This will lead to substitution of therapy which 
in most instances is more expensive, even though benefits may not differ significantly. In HIV/AIDS treatment where 
effective adherence threshold has been estimated to be around 95%, a concerted effort is needed from both health 
workers and patients alike so as to meet set targets. This research examines the effect of adherence to ART on 
treatment switching among HIV/AIDS patients in Ghana.   
Objectives
The main objective will be to determine the effect of adherence on switching from first to second line treatment 
among HIV/AIDS patients on antiretroviral therapy.
Methods
Adherence will be measured using the proportion of days covered (PDC) approach. The study period will be from 1st 
January, 2004 to 31st December, 2009. All those on first line treatment who were switched to second line treatment during 
the study period will be classified as cases. Controls will be chosen randomly from among the rest of the moving cohort 
who did not experience any therapy switch. Controls will be individually matched to cases on index date on a one control 
per case basis. To account for matching at the design stage conditional logistic regression will be used for the analysis. 
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Effectiveness of the influenza A (H1N1)pdm09 
vaccine in a community-based sample
Giedre Gefenaite1,2, Margot Tacken3, Jens Bos1, Irina Stirbu-Wagner4, Joke C. Korevaar4, 
Ronald P. Stolk2, Bert Wolters5, Marc Bijl6, Bert Niesters7, Maarten J. Postma1,2, 
Jan Wilschut8, Kristin L. Nichol9, Eelko Hak1,2
1. University of Groningen, Department of Pharmacy, PharmacoEpidemiology & PharmacoEconomics (PE2), 
Groningen, Netherlands 
2. Department of Epidemiology, University Medical Center Groningen, Netherlands 
3. Radboud University Nijmegen Medical Centre, Scientific Institute for Quality of Healthcare  (IQ 
healthcare),Nijmegen, Netherlands 
4. NIVEL, Netherlands Institute for Health Services Research, Utrecht, Netherlands
5. Municipal Health Center, Groningen, Netherlands
6. Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Netherlands 
7. Department of Clinical Virology, University Medical Center Groningen, Netherlands
8. Department of Molecular Virology, University Medical Center Groningen, Netherlands
9.  Minneapolis VA Medical Center, USA & University of Minnesota, USA
Background 
Evidence about influenza A(H1N1)pdm09 vaccine effectiveness comes mostly from case-control studies. As case-
control studies are susceptible for selection and confounding bias, we performed a population-based cohort study 
to assess the pandemic vaccine effectiveness (VE). 
Methods
We conducted a retrospective population-based cohort database study during the pandemic influenza season 
2009-2010 among 66709 18 years and older adults. The primary outcome was medically attended influenza when 
medication was prescribed (MAIm). The vaccination status was recorded if at least one dose of the influenza A(H1N1)
pdm09 vaccine was administered. Analyses were stratified by age (18-59 and 60 years and older) and adjusted for 
confounding by using the propensity score (PS) as a continuous covariate in the logistic regression. PS included 
comorbidities, MAIm and visits to the general practice during one year preceding A(H1N1)pdm09 pandemic season.. 
To adjust for unmeasured confounding we performed the analyses during a reference period when no effect of the 
vaccine was anticipated (odds ratio of one (OR=1)) and divided the OR during the period of anticipated vaccine 
effectiveness by the OR during the reference period. 
Results
The cohort consisted of 47707 (71.5%) 18-59 years old and 19002 (28.5%) 60 years and older subjects. During the 
pandemic season the vaccine reduced MAIm, notably in subjects 60 years and older (adjusted OR .18 [95% confidence 
interval (95% CI) .04-.94]). The VE analysis during the reference period has shown some remaining bias (adjusted OR .74, 
95%CI .14 – 3.92), after additional adjustment for unmeasured confounding the vaccine effectiveness slightly decreased 
(OR=.24). 
Conclusions
The vaccine showed to be effective in preventing MAIm in subjects 60 years and older, but it did not seem to have a large 
effect in younger subjects. Adjusting for unmeasured confounding led to slightly lower vaccine effectiveness.
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Identification of Priority Policy Research Issues on 
Access to Medicines in Low and Middle Income Countries
J.M. Hoebert1, M. Bigdeli2, A. K. Mantel-Teeuwisse1, L. van Dijk3 
1 UIPS, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht, The Netherlands 
2 Alliance for Health Policy and Systems Research, WHO, Geneva, Switzerland
3 Netherlands institute for health services research NIVEL, Utrecht, The Netherlands 
Background
The Alliance for Health Policy and Systems Research (AHPSR) at WHO has recently conducted a priority setting 
exercise in 15 Low and Middle Income Countries  (LMIC) to identify country level policy issues and relevant health 
policy and systems research questions in the field of Access to Medicines (ATM). These issues and research questions 
have been documented in 12 country reports and 4 regional reports. This specific study aimed to generate consensus 
about a core set of research issues, identified from these reports, that urgently require attention in order to facilitate 
policy development in the field of Access to Medicines.
Methods / Results
There were three key inputs into this specific priority setting process: a) the development of a framework for research 
and analysis, b) the analysis of relevant country reports to identify cross-cutting priority issues, and c) key informant 
interviews with a group of internationally recognized experts (n=23) to validate the identified policy issues. 
The framework that was developed brought together the areas Rational Selection and Use, Affordable Prices, 
Sustainable Financing, Reliable Health and Supply systems as developed by WHO in 2004 and the levels at which 
constraints operate as identified by Hanson et al. in 2003. These levels are Individual, Household and Community, 
Health Service Delivery, Health Sector, National Context – public policies cutting across sectors, and International and 
Regional level. The priority policy concerns were extracted by 2 independent reviewers by means of cross-checking 
and validation of discrepancies by returning to the original report and re-analysing content. The global level key 
informant interviews were held with people working at WHO, academia or NGOs or in international organizations 
such as World Bank or Global Fund.
The overview of country reports was instructive in showing which policy issues had been identified as important. 
The outcomes of the key informant interviews showed consistency with the issues identified in the reports although 
some additional issues were identified, such as the issue of substandard drugs.
Based on these outcomes, a priority agenda for health policy and system research questions on access to medicines 
will be established in March 2012. 
2 Countries included: Cambodia, Laos, Viet Nam, Thailand, Colombia, Suriname, Dominican Republic, El Salvador, Lebanon, 
Iran, Pakistan, India, Cameroon, Chad, Gabon, Congo
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The 2009 H1N1 influenza A virus outbreak: adherence 
to national prescription guidelines for oseltamivir
D. Philbert1, E.H. Fietjé1, E.C.G. van Geffen1, N.A. Winters1, and M.L. Bouvy1
1. Utrecht Institute for Pharmaceutical Scinces, Utrecht, the Netherlands
Background
The national guideline for prescribing oseltamivir during the 2009 H1N1 influenza A pandemic was adapted throughout 
the year. After August 7th, prescribers were advised to restrict prescriptions to patients with influenza symptoms as 
well as at least one additional risk factor. In this study we assessed whether oseltamivir was prescribed according 
to the national guideline, and investigated how patients used oseltamivir.
Methods
Pharmacists in 19 pharmacies belonging to the Utrecht Pharmacy Practice network for Education and Research 
(UPPER) selected all patients with a prescription for oseltamivir between August 7 2009 and February 8 2010, to be 
able to assess adherence to the most current guidelines. These patients were contacted for a structured telephone 
questionnaire.
Results
A structured questionnaire was completed for 300 patients. Of all responders, 111 (37%) received a prescription 
‘off-guideline’ (not having both flu symptoms and at least one risk factor). Responders aged over 18 with a higher 
education level were two times more likely to receive an oseltamivir prescription off-guideline than responders with 
a low education level. Nearly all responders who received oseltamivir in accordance with guideline criteria started 
treatment (184 out of 189 responders, 97.4%), while only half of the off-guideline responders started treatment (62 
out of 111 responders, 55.9%).
Conclusion
One in three patients who received an oseltamivir prescription during the H1N1 pandemic did not meet the guideline 
criteria for a prescription. In addition, nearly half of the patients who did not meet guideline criteria also did not 
start the oseltamivir course. It is important to make sure prescribers are properly informed about current guidelines, 
to reduce overprescribing due to lack of information. Furthermore, improving communication between prescribers 
and patients might help relieve patients’ concerns and increase awareness about the limited benefits of oseltamivir 
treatment in healthy individuals.
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The risk of ototoxicity in patients concomitantly 
treated for Drug resistant-TB and HIV-1 infection 
E Sagwa1,2, AK Mantel-Teeuwisse1 
1. Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands
2. Management Sciences for Health, Namibia
Introduction
In Namibia, there is a high proportion (59%) of TB patients co-infected with HIV, which complicates treatment of 
drug-resistant TB. Aminoglycosides, which are used in second-line DR-TB regimens, are known to be ototoxic. Are 
antiretrovirals ototoxic too? The data available is contradictory, limited, and inconclusive (Berke, 2010; Katijah, 2011). 
Hearing loss was common (29%) in patients on ART and being aged ≥ 35 years was a risk factor (Marra et al., 1997). 
Prospective studies are needed to determine the incidence of tinnitus and hearing loss among DR-TB/ HIV-1 co-
infected patients and the influence of the use of NRTIs on the risk of ototoxicity (Shouten et al., 2006). Drug-drug 
interactions, concomitant use of other ototoxic drugs (NRTIs?) and noise exposure may have an influence on the 
ototoxicity of aminoglycosides.
Research Question 
Does the combined use of second-line anti-TB medicines and NRTIs increase the risk of ototoxicity in patients 
concomitantly treated for DR-TB and HIV-1 infection, as compared to those treated with second-line anti-TB medicines 
alone?
Design and Methods
Prospective cohort, with 2 groups, followed up for 9 months: (1) DR-TB only (aminoglycoside-containing anti-TB 
regimens) and (2) DR-TB and NRTIs (aminoglycoside-containing anti-TB regimens + NRTIs + HIV).
Sample size calculation
Related to structure a specific central distribution facility where prescriptions were prepared for delivery was organized. 
RECASA could count on a specific budget, information system and human resources. Not all procedures were adequately 
standardized and communicated to professional involved. Consistency problems between information entered in the 
computerized system and medical records. Most of patients (91.6%) declared to be satisfied with RECASA but only 1% 
were found to be totally adherent according to MBG scale.
Cohort Expected prevalence of ototoxicity Sample size 
DR-TB therapy only (aminoglycoside-containing anti-TB regimens) 45% 108 
DR-TB + HAART
(aminoglycoside-containing anti-TB regimens + NRTIs) 70%  (about RR =1.5) 108 
Sampling
Consecutive sampling of patients initiating DR-TB treatment and DR-TB treatment + HAART, all ages, both genders, 
excluding those with prior hearing problems, prior exposure to occupational noise, other aminoglycoside treatment (e.g. 
streptomycin).
Data Analysis
Descriptive statistics; bivariate analysis-relative risk (RR), chi-square; and multivariate Cox PH analysis.
 
Results
This will be available after execution of the study. 
Conclusion and Recommendations
The findings may have implications for the improved audiological monitoring of patients on both DR-TB treatment and 
NRTI-based HAART.
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Outcome of a post-exposure prophylaxis program 
at the Korle-Bu Teaching Hospital (KBTH) in Ghana
Tetteh, R. A1, Nartey, E.T2, Lartey, M.2, Dodoo, A.N.O.2, Mantel-Teeuwisse A.K.3, Leufkens, H.G.M.3
1. Korle-Bu Teaching Hospital, Accra, Ghana
2. University of Ghana Medical School, Accra, Ghana
3. Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands
Background
The risk for occupational exposure to HIV is a serious public health problem and has been well characterized in the 
developed world. However, limited information is available about this transmission risk in a resource-constrained 
setting facing the largest burden of HIV infection. In addition, the feasibility and utilization of post-exposure 
prophylaxis (PEP) programs in these settings are unclear. Ghana has developed guidelines on the use of post 
exposure prophylaxis since the implementation of free antiretroviral in December 2003. Therefore, we examined the 
rate and characteristics of occupational exposure to HIV and the utilization of PEP among health care workers (HCW) 
and health care students (HCS) in the Korle-Bu Teaching Hospital (KBTH), the largest, urban government teaching 
hospital in Ghana. 
Methods
Demographic and clinical data on occupational exposures and their management were retrospectively collected 
from December 2005–December 2010. Data reviewed included drugs administered and adverse events reported. US 
Centers for Diseases Control guidelines were utilized to define risk exposures, for which PEP was recommended. 
Descriptive statistics and chi-square test was employed to assess association among variables. Incidence rates of 
reported exposures and trends in PEP utilization were examined using logistic regression. P-value less than 0.05 was 
considered statistically significant.
Results
Of 1930 HCW and 1400 HCS, a total of 260 and 35 exposures were reported by HCW and HCS respectively. The 
incidence rate was 13.5 and 2.5 exposures per 100 person-years (PY) respectively for HCW and HCS. Ward attendants 
reported the greatest number of exposures with an annual incidence of 38.8 per 100 PY. The incidence of high-risk 
exposures was 2.0/100 PY (n = 65); 60.0% occurred during a procedure of disposing of a needle and 24.6% during 
a canula insertion. A total of 98.5% (64) patients of high-risk cases began an extended PEP regimen of which only 
54.7% completed it with 37.5% who stopped due to adverse drug reactions (ADR). The most experienced ADR was 
nausea which was reported by a total of 69.8% of those given 3TC/AZT/PI, 29.5% of those given 3TC/AZT and 33.3% 
of those administered 3TC/AZT/EFV. There was no HIV seroconversion identified. 
Conclusions  
The PEP service in the Korle Bu Teaching Hospital has revealed interesting outcomes which should be used to 
improve on the policy adopted for the service. With implementation of a hospital-wide PEP program, there was 
an encouraging decrease of high-risk exposures over time and appropriate use of PEP. More sensitization sessions 
should be held for the staffs especially ward attendants as they continue to report late for PEP despite the fact they 
are relatively more prone to having a needle stick injury.
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